There are hundreds of GSK3β inhibitor-related patents registered, and the main therapeutic areas covered are cancer, neurological diseases, and diabetes [https://www.cortellis.com/drugdiscovery/home?locale=en-US, accessed on 10 May 2022]. This evidence concerns the gene GSK3B and cancer.